Aurisco Pharmaceutical Co Ltd

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.